{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:07:41Z","timestamp":1778638061144,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interferon (IFN)-\u03b1 is widely used for the treatment of chronic hepatitis B (CHB) infection due to the high rate of hepatitis B surface antigen (HBsAg) seroconversion. However, IFN-\u03b1 treatment has a number of side effects. Thus, identification of molecular biomarkers to predict IFN-\u03b1 therapeutic effect would be useful in the clinic. In this study, we aimed to investigate the role of retinoic acid-inducible gene-I (RIG-I) in prediction of IFN-\u03b1 curative effect of CHB patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 65 CHB patients treated with pegylated IFN-\u03b1 weekly for 48 weeks were enrolled. Realtime PCR was performed for detection of RIG-I and IFN-stimulated gene (ISG) expression. In vitro, the HepG2 cells were transfected with siRNA and levels of RIG-I and anti-HBV proteins were detected by western blot. The P-values were calculated in SPSS 18.0. The statistical significance level was accepted as P&lt;0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this study, we found RIG-I expression in peripheral blood mononuclear cells was higher in responder than non-responder CHB patients treated with IFN-\u03b1 therapy. In HBV-transfected HepG2 and Huh7 cells, RIG-I enhanced IFN-\u03b1 response by promoting anti-HBV protein expression such as double-stranded RNA-dependent protein kinase (PKR), oligoadenylate synthetase (OAS), adenosine deaminase (ADAR1) and Mx protein. Knocking down of RIG-I could downregulate the expression of these proteins. Inhibited RIG-I expression by RIG-I siRNA deceased STAT1 phosphorylation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results revealed RIG-I enhanced IFN-\u03b1 response by promoting antiviral protein expression via the STAT1 pathway. RIG-I may be a new predictive factor for prediction of IFN-\u03b1 efficacy in CHB patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3239","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T09:23:31Z","timestamp":1527067411000},"page":"575-583","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["RIG-I Enhances Interferon-\u03b1 Response by Promoting Antiviral Protein Expression in Patients with Chronic Hepatitis B"],"prefix":"10.1177","volume":"23","author":[{"given":"Shu","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"First Clinical College, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinpiao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"First Clinical College, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"First Clinical College, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qishui","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"First Clinical College, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,10,1]]},"reference":[{"key":"bibr1-IMP3239","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.116"},{"key":"bibr2-IMP3239","doi-asserted-by":"publisher","DOI":"10.1159\/000360941"},{"key":"bibr3-IMP3239","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360618"},{"key":"bibr4-IMP3239","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.11.011"},{"key":"bibr5-IMP3239","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.12.016"},{"key":"bibr6-IMP3239","first-page":"888","volume":"23","author":"Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association, Hou JL, lai W.","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"bibr7-IMP3239","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2172-1"},{"key":"bibr8-IMP3239","doi-asserted-by":"publisher","DOI":"10.7150\/thno.10636"},{"key":"bibr9-IMP3239","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","volume":"12","author":"Qi X.","year":"2007","journal-title":"Antivir Ther"},{"key":"bibr10-IMP3239","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2011.10.011"},{"key":"bibr11-IMP3239","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.09.039"},{"key":"bibr12-IMP3239","doi-asserted-by":"publisher","DOI":"10.1038\/nature10537"},{"key":"bibr13-IMP3239","doi-asserted-by":"publisher","DOI":"10.1038\/35073080"},{"key":"bibr14-IMP3239","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.09.050"},{"key":"bibr15-IMP3239","doi-asserted-by":"publisher","DOI":"10.2174\/1389200215666140605130935"},{"key":"bibr16-IMP3239","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25749"},{"key":"bibr17-IMP3239","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.12.009"},{"key":"bibr18-IMP3239","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26436"},{"key":"bibr19-IMP3239","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24364"},{"key":"bibr20-IMP3239","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:35Z","timestamp":1777380755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,1]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.3851\/IMP3239"],"URL":"https:\/\/doi.org\/10.3851\/imp3239","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,1]]}}}